Navigation Links
Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Date:3/25/2009

ung and ovarian cancers that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists.

The primary objective of the trial was to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN when administered in combination with gemcitabine. Secondary objectives include the evaluation of immune response to the drug combination, the body's response to the drug combination compared to chemotherapy alone and any evidence of anti-tumour activity.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

Gemzar(R) is indicated for NSCLC, breast, pancreatic and ovarian cancer. For more information about Gemzar(R), please visit www.gemzar.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. and U.S. combination REOLYSIN/gemcitabine clinical trials and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue researc
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
3. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
4. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
5. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
7. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
8. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
9. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... , May 20, 2015  Health eCareers, the ... healthcare organizations with job seekers looking for the ... a new mobile and online tool dedicated exclusively ... industry. SHIFT enables employers to quickly ... travel nursing, per diem and other temporary positions, ...
(Date:5/20/2015)...  Haemonetics Corporation (NYSE: HAE ) announced today ... present at The Jefferies 2015 Global Healthcare Conference in ... st , 2015 at 8:30am Eastern time.  ... via webcast at: http://wsw.com/webcast/jeff88/hae ... is a global healthcare company dedicated to providing innovative ...
(Date:5/20/2015)... DUBLIN , May 19, 2015 Research ... announced the addition of the "Bone Morphogenetic ... Spinal Fusion, Trauma, Reconstructive and Oral - Maxillofacial) ... and Forecast 2014 - 2022" report to ... proteins market is studied based on the types ...
(Date:5/20/2015)... The Greater Gift Initiative, Inc ., ... to announce they are donating 10,010 vaccines today in ... the effort and commitment of clinical trial volunteers who ... in 2014. , With a mission to advance ... trial participation, GGI supports International Clinical Trials Day and ...
Breaking Biology Technology:Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3Global Bone Morphogenetic Proteins Market Industry Analysis 2014 - 2022 2The Greater Gift Initiative Donates over 10,000 Vaccines in Honor of International Clinical Trials Day 2
... SEATTLE, WA, May 30 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ... that data from clinical trials for three of the ... of Clinical Oncology (ASCO) Annual Meeting on May 30, ... data from the Phase 2b trial of Stimuvax(R) in ...
... May 29 Martek Biosciences Corporation (Nasdaq: MATK ... 8th Annual Needham Life Sciences Conference which is scheduled to ... Hotel in New York City. Peter L. Buzy, Chief ... 2009, at 2:30 p.m. Eastern Time.A live audio webcast of ...
... Exiqon Diagnostics, announced today a strategic commercial partnership ... solution provider for oncologists that offers clinically useful ... Exiqon Diagnostics, a leader in individualizing cancer ... EDR(R) Assay) clinical laboratory services, will become a ...
Cached Biology Technology:Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Exiqon Diagnostics Partners With MedTrust Online to Promote KRAS Mutation Analysis and Other Innovative Molecular Oncology Diagnostic Services to Oncologists 2Exiqon Diagnostics Partners With MedTrust Online to Promote KRAS Mutation Analysis and Other Innovative Molecular Oncology Diagnostic Services to Oncologists 3
(Date:5/19/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/18/2015)... , May 18, 2015 Fingerprint ... sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if ... June until and including Q3 2015 and the sensors will ... . Communicated order values for 2015 hereby amount to 740 ... Q1 2015 of 140 MSEK and a number of smaller ...
(Date:5/11/2015)... 2015  Synaptics Incorporated (NASDAQ: SYNA ), ... announced the appointment of Wajid Ali ... reporting to Rick Bergman , President and ... Officer, Kathleen Bayless , who announced her ... Ali brings extensive financial management expertise to Synaptics, ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... since insects developed a taste for vegetation, plants have ... their neighbors for light to grow, or, invest directly ... of scientists at the Salk Institute for Biological Studies ... a la Agronoma (IFEVA) has discovered how plants weigh ...
... virus (HIV) adapts so well to the body,s defense ... with the ever-changing immunological profile of the virus, according ... (UAB) and the University of Oxford in England. ... by spelling out at least 14 different "escape mutations" ...
... of London have discovered how changes to a frog,s immune ... which is devastating frog populations across the UK. ... by a foreign virus which is estimated to be killing ... When it strikes garden ponds, the surrounding lawn becomes strewn ...
Cached Biology News:Understanding natural crop defenses 2Understanding natural crop defenses 3HIV adapts to 'escape' immune response 2Frog's immune system is key in fight against killer virus 2
... MMP-3, Human, Assay, 96 wells. ELISA.Specific ... and complexed MMP-3. No cross-reactivity with MMP-1, ... ng/ml.Suitable for use with cell culture supernatant, ... at -15 to -30 C. Category: ...
... Steady gravity-fed delivery of buffer ... animal perfusion. Rat version. In Vivo ... results--Steady gravity-fed delivery of buffer and ... Easy to setup, use and clean--Complete ...
... 8 micro-bore tubes to 1 outflow ... tips, Rapid (several millisecond) solution change ... prevention , Solid construction 360, 250 ... For mounting on any micromanipulator Available ...
... The steadylite plus assay ... High assay sensitivity, Designed for ... Suitable for higher density microplates ... plates, Odor free, Convenient storage ...
Biology Products: